Research News and Research

RSS

Push to delay Australia’s R&D tax credit will hurt start-up innovators

Much-needed change to Australia’s R&D tax system is amongst legislative bills to be re-introduced to Parliament as it resumes this week. AusBiotech urges MPs to support the swift passage of the R&D Tax Credit legislation and the Government to persist with its introduction.

29 Sep 2010

Unique genetic markers point to patient response to SCV-07 treatment

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that researchers have identified two unique gene clusters that differentiated subjects who responded to treatment in the Company’s phase 2a proof of concept study of SCV-07 for the prevention of severe oral mucositis (OM; WHO grades 3-4) in patients with advanced head and neck cancer.

29 Sep 2010

Swine flu no longer a threat to Americans: Report

According to the latest research most Americans are immune to the swine flu virus. Results of the study by the National Institute of Allergy and Infectious Diseases, published in the journal mBio show that around 59 percent of the 310 million U.S. population has developed immunity to H1N1 either from exposure to similar viruses, vaccination, or natural H1N1 infection.

29 Sep 2010

Malaria vaccine close to reality

A successful and effective malaria vaccine could be available in Africa by 2015 revealed a co-inventor of the shot against the killer disease, Tuesday. Advance trials of the RTS,S vaccine against falciparum malaria are under way in seven African countries. This variety of malaria is the deadliest and trials are said to be showing encouraging results according to GlaxoSmithKline researcher Joe Cohen, who has been working on developing the vaccine for over 20 years.

29 Sep 2010

Dems expect 9/11 'first responders' bill to pass today

CongressDaily: "At the urging of what one aide called 12 'pushy' New York lawmakers, House Democratic leaders plan to bring to the floor today legislation that would extend healthcare aid to 9/11 first responders. ... The $7.4 billion measure would provide health monitoring and treatment benefits to first responders and survivors of the Sept. 11, 2001, terrorist attacks.

29 Sep 2010

Political cartoon: 'Witchcraft?'

Kaiser Health News provides this fresh take on health policy developments with "Witchcraft?" by Nate Beeler.

29 Sep 2010

NeurAxon closes convertible debenture financing

NeurAxon, Inc., a development-stage pharmaceutical company that is designing and developing next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), today announced that it has closed a convertible debenture financing in which the convertible debentures are convertible under specified circumstances into existing class B preferred shares for a total of approximately $14 million.

29 Sep 2010

Senesco fiscal 2010 revenue decreases to $140,000

Senesco Technologies, Inc. reported financial results for the 12 months ended June 30, 2010 ("Fiscal 2010").

29 Sep 2010

NINDS establishes new sites as part of Morris K. Udall Centers of Excellence in Parkinson's Disease Research

The National Institute of Neurological Disorders and Stroke (NINDS), a component of the National Institutes of Health, has established two new sites as part of the Morris K. Udall Centers of Excellence in Parkinson's Disease Research. The NINDS grants will provide a five-year investment totaling more than $16 million for Emory University in Atlanta and the Feinstein Institute for Medical Research in Manhasset, N.Y.

29 Sep 2010

NIAID study utilizes Biojector B2000 system to explore syringe, needle benefits

Bioject Medical Technologies Inc., a leading developer of needle-free injection therapy systems, today announced that its unique Needle-Free Injection Therapy (NFIT) system, the Biojector 2000, is being utilized in a study sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) which is part of the U.S. National Institutes of Health (NIH).

29 Sep 2010

IN.PACT drug-eluting balloons show promising results for superficial femoral artery disease treatment

Advancing research on drug-eluting balloons for the treatment of coronary and peripheral artery disease, Medtronic, Inc., today announced the latest results from the IN.PACT drug-eluting balloon (DEB) clinical program presented last week at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 conference.

29 Sep 2010

Neurons that control sexual behavior mapped

How the bundles of neurons in the brain controls behaviour remains an ongoing mystery. Researchers from the Institute of Molecular Pathology (IMP), in Vienna, Austria, and the Laboratory of Molecular Biology (LMB/MRC), Cambridge, United Kingdom, have mapped neurons of the fruit fly, Drosophila, that controls sexual behavior. "We literally untangled the mess of wires in the fly brain and laid the ground plans for investigating a complex behavior in a simple organism," says Jai Yu, whose doctoral work is published in Current Biology.

29 Sep 2010

Pulmokine receives NIH SBIR grants to develop novel treatments for PAH

YM BioSciences Inc., today reported that Pulmokine Inc. (Slingerlands, New York), a licensee of several small molecule compounds from YM, has been awarded two National Institutes of Health (NIH) Small Business Innovation Research (SBIR) grants. The grants, totaling more than US$650,000, are Phase I awards to develop novel treatments for Pulmonary Arterial Hypertension (PAH).

29 Sep 2010

New program offers options for fertility preservation in children with cancer

It is estimated that 1 in 500 children will be diagnosed with a form of childhood cancer. Fortunately, with the use of aggressive treatment modalities, more than 75% of these children will be cured. Therefore, many of these children and parents are looking beyond the cancer at important quality of life issues and guiding their treatments to assure "normal" post-cancer survivorship.

29 Sep 2010

First Edition: September 29, 2010

In today's headlines, reports about the continuing politics surrounding the health overhaul, as both parties vie for the loyalty of older voters and First Lady Michelle Obama steps up efforts to promote the new law.

29 Sep 2010

NIH trial selects Inovio's PENNVAX-G DNA vaccine candidate to evaluate HIV-1 prevalent

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector boost regimen that was developed to protect against diverse subtypes of HIV-1 prevalent in North America, Europe, Africa, and South America.

29 Sep 2010

Researchers primed to contribute next phase in search and discovery: Elsevier survey

Elsevier, a world-leading publisher of scientific, technical and medical information products and services, today released highlights from a new survey that reveals researchers around the globe are not only ready for the next phase in search and discovery, but also prepared to actively contribute to making it a reality.

29 Sep 2010

Cancer-causing mutations have minimum effect on tumor growth: Research

Individual cancer causing mutations have a minute effect on tumor growth, increasing the rate of cell division by just 0.4 percent on average, according to new mathematical modeling by scientists at Harvard University, Johns Hopkins University, and other institutions.

29 Sep 2010

Sysmex to supply medical hematology analyzers to USAMMA

Sysmex, a global leader in medical diagnostic testing equipment and information systems technology, today announced that the company has been awarded a BPA Equipment purchase contract agreement. The contract was issued by USA Medical Research ACQ Activity for the U.S. Army Medical Material Agency (USAMMA).

From Sysmex America, Inc. 29 Sep 2010

Patients' right to be involved in own medical care

Twelve years ago, then 28-year-old graduate student Brian Zikmund-Fisher was forced into the toughest choice of his life: Die from a blood disorder within a few years or endure a bone marrow transplant that could cure him or kill him in weeks.

29 Sep 2010